Ettl A, Daxer A, Göttinger W, Schmid E
Department of Ophthalmology, University of Innsbruck, Austria.
Br J Ophthalmol. 2004 Jan;88(1):44-7. doi: 10.1136/bjo.88.1.44.
To investigate the efficacy of verapamil eye drops for inhibition of diabetic cataract in rats.
Diabetes was induced in 69 male Sprague-Dawley rats by an intraperitoneal injection of streptozotocin (65 mg/kg body weight). One group (DV) of animals was treated by instillation of one drop of 0.2% RS-verapamil hydrochloride in both eyes three times daily for 8 weeks. The placebo treated group (D) received the vehicle solution only. After 8 weeks the lenses were removed, inspected, and photographed using bright and dark field illumination. The transmission of He-Ne laser light was measured in the optical axis of each lens in order to determine the turbidity coefficient (t) as a measure of central lens opacity. Following digital image analysis, the integrated density as a measure of central and mid-peripheral opacities was determined.
Lenses of both groups developed peripheral cortical opacities not affecting the optical axis. Advanced and paracentral cortical opacities were present in 10 (16.7%) of the placebo treated lenses (D) and two (3.8%) of the verapamil treated lenses (DV). Complete corticonuclear cataract developed in four (6.7%) of the lenses from group D but none of the lenses from group DV. The mean lens turbidity t was determined to be 0.019 (SEM 0.002) mm(-1) (n = 52) in the verapamil treated diabetic rats (DV) and 0.042 (0.008) mm(-1) (n = 60) in the placebo treated group (D). This difference was statistically significant (p = 0.0054). The mean integrated density was 274.91 (22.5) in group D (n = 60) and 196.28 (20.7) in group DV (n = 37). This difference was also significant (p = 0.0037).
Verapamil eye drops 0.2% administered three times daily are effective in inhibiting the progression of lens opacities in streptozotocin diabetic rats.
研究维拉帕米滴眼液对大鼠糖尿病性白内障的抑制作用。
通过腹腔注射链脲佐菌素（65mg/kg体重）诱导69只雄性Sprague-Dawley大鼠患糖尿病。一组动物（DV组）每天双眼滴注一滴0.2%的盐酸RS-维拉帕米，共8周，每日3次。安慰剂治疗组（D组）仅接受赋形剂溶液。8周后取出晶状体，用明场和暗场照明进行检查和拍照。测量每个晶状体光轴上的氦氖激光透射率，以确定浑浊系数（t）作为晶状体中央混浊程度的指标。经过数字图像分析，确定综合密度作为中央和中周边混浊程度的指标。
两组晶状体均出现不影响光轴的周边皮质混浊。安慰剂治疗组（D组）10只（16.7%）晶状体出现晚期和旁中央皮质混浊，维拉帕米治疗组（DV组）2只（3.8%）出现此类情况。D组4只（6.7%）晶状体发展为完全皮质核性白内障，而DV组无一只出现。维拉帕米治疗的糖尿病大鼠（DV组）晶状体平均混浊度t为0.019（标准误0.002）mm-1（n = 52），安慰剂治疗组（D组）为0.042（0.008）mm-1（n = 60）。差异具有统计学意义（p = 0.0054）。D组（n = 60）平均综合密度为274.91（22.5），DV组（n = 37）为196.28（20.7）。差异也具有统计学意义（p = 0.0037）。
每日3次给予0.2%的维拉帕米滴眼液可有效抑制链脲佐菌素诱导的糖尿病大鼠晶状体混浊的进展。
